What Mediar Therapeutics does

Mediar Therapeutics is a clinical-stage biotechnology company founded in 2019 as a spinout of Massachusetts General Hospital and Brigham and Women's Hospital (Mass General Brigham), based in Boston, Massachusetts. The company develops first-in-class human IgG1 monoclonal antibodies designed to disable the myofibroblast — the pathogenic cell that drives collagen deposition, extracellular matrix accumulation, and progressive organ scarring in fibrosis — by targeting novel fibrotic mediators WISP1, EphrinB2, and SMOC2. Its clinical pipeline comprises MTX-463 (anti-WISP1, Phase 2 WISPer trial in idiopathic pulmonary fibrosis), MTX-474 (anti-EphrinB2, Phase 2 EncompaSSc trial in diffuse cutaneous systemic sclerosis), and MTX-439 (anti-SMOC2, Phase 1 in chronic kidney disease), plus a portfolio of bi-specific antibody programs in lead optimization in oncology and inflammatory bowel disease.

The company's business model is B2B/partnership-driven: Mediar generates revenue exclusively through out-licensing clinical-stage assets to large pharmaceutical partners rather than direct product sales, exemplified by a January 2025 global licensing agreement with Eli Lilly for MTX-463 that provides $99M in upfront and near-term milestone payments, up to $687M in development and commercialization milestones, and high-single to low-double-digit tiered royalties on future net sales. Pre-commercial operations are funded through venture capital, with approximately $181M+ raised across a 2021 seed round led by Pfizer Ventures, a March 2023 $85M Series A co-led by Novartis Venture Fund and Sofinnova Partners, and a January 2026 oversubscribed $76M Series B co-led by Amplitude Ventures and ICG. Mediar also runs investigator-sponsored and company-sponsored clinical trials globally and relies on specialized discovery (Alloy Therapeutics) and imaging analytics (Qureight) partnerships to accelerate and de-risk its pipeline. Approximately 40+ team members operate across antibody engineering, clinical operations, regulatory, quality, biostatistics, translational medicine, CMC, and data management functions under a leadership team whose fibrosis experience includes prior senior roles at Pfizer, Gilead, Biogen, and Takeda.

Name

Mediar Therapeutics

Legal name

Mediar Therapeutics, Inc.

Website

https://mediartx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibodies that target the myofibroblast to halt and reverse fibrosis, with three clinical programs in IPF, systemic sclerosis, and chronic kidney disease, and a global licensing partnership with Eli Lilly for its lead asset.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

Keywords

• Fibrosis therapeutics
• Monoclonal antibody therapy
• Anti-fibrotic drugs
• Clinical-stage biotechnology
• Biopharmaceutical R&D

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Out-licensing of clinical-stage assets: Generates revenue via global licensing deals with large pharmaceutical partners. Eli Lilly deal for MTX-463 (anti-WISP1) provides $99M in upfront and near-term milestone payments, up to $687M in additional development and commercialization milestones, plus high-single to low-double-digit tiered royalties on future net sales. Deal is back-weighted on milestones.
2. Private equity financing (pre-commercial): Clinical-stage biotech currently pre-revenue on product sales; capital is raised via venture financing rounds. Has raised $105M (Series A $85M co-led by Novartis Venture Fund and Sofinnova Partners in 2023, plus prior $20M seed) and an oversubscribed $76M Series B in January 2026 co-led by Amplitude Ventures and ICG.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target the myofibroblast — the key pathogenic cell driving fibrosis — to halt and reverse scarring in fibrotic diseases. The pipeline includes three clinical-stage programs: MTX-463 (anti-WISP1) in Phase 2 for idiopathic pulmonary fibrosis (IPF), MTX-474 (anti-EphrinB2) in Phase 2 for diffuse cutaneous systemic sclerosis (SSc), and MTX-439 (anti-SMOC2) in Phase 1 for chronic kidney disease (CKD), plus bi-specific antibody programs in lead optimization for oncology and IBD indications.

Product overview

No product/service information was available in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

• MTX-463 (anti-WISP1 antibody) MTX-463 is a first-in-class human IgG1 monoclonal antibody designed to neutralize WISP1-mediated fibrotic signaling, with activity spanning lung and liver fibrosis indications. It is currently in Phase 2 development for idiopathic pulmonary fibrosis (IPF) under a global licensing partnership with Eli Lilly.
• MTX-474 (anti-EphrinB2 antibody) MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling that drives myofibroblast activation, tissue remodeling and fibrosis of skin, lungs and heart. It is currently in Phase 2 development for diffuse cutaneous Systemic Sclerosis (SSc) under the EncompaSSc clinical trial.
• MTX-439 (anti-SMOC2 antibody) MTX-439 is a first-in-class anti-SMOC2 antibody targeting a secreted matricellular protein that promotes extracellular matrix assembly, cell adhesion and kidney fibrosis. It is currently in Phase 1 development for chronic kidney disease (CKD), including diabetic kidney disease.
• Bi-specific antibody programs Pipeline of novel bi-specific antibodies in lead optimization designed to further unlock validated anti-fibrotic mechanisms; currently advancing two bi-specific programs in Oncology and IBD indications.

Quantifiable outcome

• $99M in upfront and near-term milestone payments from Eli Lilly plus up to $687M in development/commercialization milestones and tiered royalties for global rights to MTX-463
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• QureightcoreImplementation/ SI/ Consulting Partner · 13 May 2026Qureight is an imaging CRO supporting Mediar's Phase 2 EncompaSSc clinical trial of MTX-474 in diffuse cutaneous Systemic Sclerosis. Qureight provides its AI-powered 3D quantitative imaging analytics platform — including Glass8, Fibr8, Vascul8, Air8, and Lung8 models — to analyze HRCT lung images from trial participants at screening and at 24 weeks following treatment.
• Alloy TherapeuticscoreStrategic or Co-development Partner · 2 February 2026Antibody discovery collaboration leveraging Alloy's ATX-Gx human transgenic mouse platform, genetic immunization strategies, and AI/ML-enabled discovery workflows. Delivered differentiated binders against challenging fibrosis targets, accelerating Mediar's development timeline by approximately six months and enabling multiple programs to enter clinical development ahead of schedule. The collaboration informed Mediar's lead program MTX-463, now in Phase 2 for IPF. Alloy supports 200+ partners globally across more than 100 active drug programs.
• Eli Lilly and CompanyflagshipOEM/ Whitelabel/ Licensing Partner · 10 January 2025Global licensing agreement (announced January 10, 2025) granting Eli Lilly worldwide development and commercialization rights to Mediar's anti-WISP1 antibody MTX-463 for idiopathic pulmonary fibrosis (IPF). Deal includes $99M in upfront and near-term milestone payments, up to $687M in additional development and commercialization milestones, plus high-single to low-double-digit tiered royalties on future net sales. First patient was dosed in the Phase 2 WISPer trial in June 2025 under this partnership.
• Alexandria Real Estate EquitiesminorOthersListed on Mediar's investor page; a life sciences-focused real estate investment trust (REIT) that develops and leases lab space to biotech tenants.
• Mass General Brigham (founding institution)coreStrategic or Co-development PartnerMediar was founded in 2019 as a spinout from Massachusetts General Hospital and Brigham and Women's Hospital (Mass General Brigham) based on fibrosis research from those institutions' labs. Co-founders include researchers whose work on the myofibroblast and targets such as EphrinB2 (Nature Medicine 2017) and SMOC2 (JCI Insight 2017) underpins Mediar's pipeline.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pliant Therapeutics: Clinical-stage biotech developing integrin-targeted therapeutics for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Directly comparable to Mediar as a fibrosis-focused biotech with programs in IPF and adjacent fibrotic indications.
• Blade Therapeutics: Clinical-stage company developing anti-fibrotic therapies for IPF and other fibrotic diseases, including a Phase 2 program in IPF. Closely aligned with Mediar in indication focus and fibrosis-modality strategy.
• Endeavor BioMedicines: Clinical-stage fibrosis company with a lead IPF program (talotrexin/ENV-101). Same indication and similar clinical-stage positioning as Mediar's MTX-463, competing for the same IPF patient population and partnership interest.
• Avalyn Pharma: Clinical-stage biotech developing inhaled therapies for IPF and progressive pulmonary fibrosis. Direct competitor in IPF, addressing the same patients Mediar is recruiting for in the WISPer trial.

Broad incumbents

• FibroGen: Established public biotech with approved roxadustat and a broader pipeline including IPF (pamrevlumab). Comparable as a fibrosis-focused company with both clinical assets and a track record of large pharma partnerships.
• Boehringer Ingelheim (nintedanib/Ofev): Markets nintedanib (Ofev), the standard-of-care anti-fibrotic for IPF. Represents the incumbent that any new IPF therapy (including Mediar's MTX-463) must displace or combine with.
• United Therapeutics: Commercial-stage pulmonary company with treprostinil and a growing portfolio in pulmonary hypertension and IPF (Tyvaso DPI). Comparable as a larger pulmonary fibrosis player with both commercial and clinical assets.
• Roche / Genentech: Major pharma with active IPF and systemic sclerosis programs (e.g., Roche's idiopathic pulmonary fibrosis research and the legacy pirfenidone franchise through legacy partnerships). Likely counterpart for future out-licensing transactions from Mediar.
• AbbVie (IPF program / telisotuzumab): Major pharma with fibrosis and immunology franchise and active IPF/SSc research. Likely licensor or competitor in the fibrosis space where Mediar is positioning its pipeline.

Emerging players

• Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for fibrotic diseases including IPF. Emerging overlap with Mediar in mechanism (integrins vs myofibroblast) and indication space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mediar-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediar Therapeutics